eltrombopag
SpainDrugs containing this active substance
-
It is used to help increase the number of platelets in the blood. It is prescribed to treat immune thrombocytopenia (primary) in patients 1 year of age or older who have not responded to other treatments, and to treat low platelet levels in adults with hepatitis C virus infection.
Form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg Manufacturer: Cipla Europe N.V.
-
It is used to help increase the number of platelets in the blood. It is prescribed to treat immune thrombocytopenia (ITP) in patients 1 year of age or older who have not responded to other treatments, and also to treat low platelet levels in adults with hepatitis C virus infection.
Form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg Manufacturer: Cipla Europe N.V.
-
It is used to help increase the number of platelets in the blood. It is prescribed to treat immune (primary) thrombocytopenia in patients 1 year of age or older who have not responded to other treatments, and to treat low platelet levels in adults with hepatitis C virus infection.
Form: tablets, film-coated
Active substance Dosage eltrombopag 75 mg Manufacturer: Cipla Europe N.V.
-
It is used to help increase the number of platelets in the blood in cases of immune thrombocytopenia (primary) in patients over 1 year of age who have not responded to other treatments. It is also used to treat low platelet levels in adults with hepatitis C virus infection and in patients with severe aplastic anemia (SAA).
Form: powder for preparation of oral suspension
Active substance Dosage eltrombopag 25 mg Manufacturer: Novartis Europharm Limited
-
It is used to help increase the number of platelets in the blood in patients with immune thrombocytopenia (ITP), in adults with low platelet levels due to hepatitis C virus infection, and in patients with low blood cell counts caused by severe aplastic anemia (SAA).
Form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg Manufacturer: Novartis Europharm Limited
-
It is used to help increase the number of platelets in the blood in cases of immune (primary) thrombocytopenia in patients over 1 year of age who have not responded to other treatments, to treat low platelet levels in adults with hepatitis C virus infection, and for patients with low blood cell counts due to severe aplastic anemia.
Form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg Manufacturer: Novartis Europharm Limited